Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 3–4 (1 January 2008) | doi:10.1038/nbt0108-3
Merck's HIV vaccine flop brings vectors under closer scrutiny
Abstract
The recent failure in phase 2 of Merck's HIV vaccine was a devastating blow to the AIDS community.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
